Noxopharm (ASX:NOX) has announced an expanded work program for 2025 with its strategic partner, Melbourne’s Hudson Institute of Medical Research.
Hudson Institute is an Australian medical research organisation focused on discovery science and translational research.
The partnership and in-licensed technology are components of Noxopharm's Sofra platform, via which it is developing a portfolio of assets, including the SOF-SKN topical skin medication for lupus and the SOF-VAC program for mRNA vaccines and therapeutics enhancement.
Noxopharm said the updated contract will enable it and the Hudson Institute team to advance the Sofra platform further. This includes expanding research into critical inflammation sensors such as TLR7, TLR8, RIG-I, and cGAS and exploring promising targets such as TLR3 and TLR9.
Hudson Institute director and CEO Professor Elizabeth Hartland said, “Our collaboration with Noxopharm continues to go from strength to strength as the team extends its research program to explore more innovations in combatting inflammation and disease. It is also highly encouraging to see a first clinical trial around the corner, which is a major milestone that demonstrates the success of our ongoing partnership.”
Noxopharm CEO Dr Gisela Mautner added, “We are working closely with the Hudson Institute team to rapidly expand our portfolio and identify new commercial opportunities arising from this research. The upcoming HERACLES trial demonstrates our ability to transition concepts from the research stage into the clinic. As the RNA market continues to grow, we aim to position Noxopharm as a leading Australian company in this dynamic field."